. 2014 Dec 23;59(1):53–58. doi: 10.1128/AAC.03633-14

TABLE 2.

Pharmacodynamic parameters from the neutropenic murine thigh infection model for innovator and generic ciprofloxacin against P. aeruginosa PAO1^a

Product	E_max (log₁₀ CFU/g)	ED₅₀ (mg/kg/day)	N	Adjusted R²	S_y\|x (log₁₀)	fAUC/MIC
Product	E_max (log₁₀ CFU/g)	ED₅₀ (mg/kg/day)	N	Adjusted R²	S_y\|x (log₁₀)	BD	3LKD
Bayer	8.39 ± 0.17	14.1 ± 0.59	1.95 ± 0.13	0.988	0.33	26.7 ± 0.82	70.5 ± 4.20
Corpaul	8.28 ± 0.51	13.3 ± 1.69	1.80 ± 0.33	0.966	0.62	28.4 ± 1.19	76.1 ± 5.10
Vitalis	8.56 ± 0.39	16.2 ± 1.53	1.62 ± 0.18	0.987	0.37	29.5 ± 1.60	86.9 ± 8.16
Ryan	8.29 ± 0.43	13.2 ± 1.41	1.82 ± 0.28	0.974	0.53	24.9 ± 1.83	71.2 ± 10.2
Blaskov	8.21 ± 0.25	12.3 ± 0.83	2.03 ± 0.24	0.980	0.41	24.1 ± 1.30	68.0 ± 8.24

The P value from global curve-fitting analysis was 0.5351. E_max, maximum effect; ED₅₀, 50% effective dose; N, Hill's slope; adjusted R², adjusted coefficient of determination; S_y|x, standard error of estimate; BD, bacteriostatic dose; 3LKD, 3-log killing dose.